So, triplet therapy is not advised? It wasn't covered. ADT + ARSI + Docetaxel

Actually, triplet therapy is a recommended treatment option for certain patients with advanced prostate cancer, and it's well-supported by current evidence.

What Triplet Therapy Is

Triplet therapy combines three medications:

• ADT (androgen deprivation therapy/hormone therapy like Lupron)
• ARSI (androgen receptor signaling inhibitor - drugs like abiraterone, enzalutamide, or darolutamide)
• Docetaxel (chemotherapy)

Current Guidelines and Evidence

According to NCCN Guidelines for Patients, triplet therapy is specifically listed as a treatment option for advanced-stage prostate cancer. The guidelines include combinations like:

• ADT + abiraterone (Zytiga) + docetaxel
• ADT + enzalutamide (Xtandi) + docetaxel
• ADT + darolutamide (Nubeqa) + docetaxel

The ARASENS trial, as discussed in Cancer Commons expert webinars, demonstrated that darolutamide combined with ADT and docetaxel "delayed progression and improved survival" in patients with hormone-sensitive metastatic prostate cancer.

When It's Recommended

Triplet therapy is typically considered for patients with:

• High-volume metastatic disease (multiple bone or organ metastases)
• High-risk features
• Newly diagnosed hormone-sensitive metastatic prostate cancer

Important Considerations

The decision depends on several factors:

• Your overall health and ability to tolerate chemotherapy
• Disease burden and aggressiveness
• Your treatment goals and preferences
• Potential side effects

This is definitely a conversation to have with your oncologist about whether triplet therapy is appropriate for your specific situation, as it can be more intensive than doublet therapy (ADT + ARSI alone) but may offer better outcomes for certain patients.